Status:
RECRUITING
Post-acute COVID-19 Sequelae in Denmark
Lead Sponsor:
Hvidovre University Hospital
Conditions:
Non-communicable Disease
COVID-19
Eligibility:
All Genders
18+ years
Brief Summary
Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function fo...
Detailed Description
The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase of COVID-19) can manifest with reduced function in multiple organ systems, with a particular focus on the lungs, ca...
Eligibility Criteria
Inclusion
- Has a blood sample in the clinical biobank related to the OBS-COVID index admission
- Aged above 18 years at time of index-admission
Exclusion
- Patients without a Danish personal identification number
- Patients who do not understand or speak Danish
Key Trial Info
Start Date :
September 10 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT06191302
Start Date
September 10 2024
End Date
March 1 2026
Last Update
March 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Copenhagen University Hospital, Amager and Hvidovre
Hvidovre, Denmark, 2650